key: cord-0013527-zm8b1i3t authors: da Silva, Juliana C. R. Alves; de Azevedo, Kesley Pablo Morais; Farinasso, Cecília Menezes; da Silva, Dayde Lane Mendonça; Stefani, Cristine; Figueiredo, Ana Cláudia Morais Godoy; de Souza, Patrícia Medeiros; Piuvezam, Grasiela; Capucho, Helaine Carneiro title: Placebo use and outcome quality: A protocol for systematic review and meta-analysis date: 2020-10-30 journal: Medicine (Baltimore) DOI: 10.1097/md.0000000000022915 sha: bb356d0c0b70f34a1ac01f83589bac58877c3118 doc_id: 13527 cord_uid: zm8b1i3t BACKGROUND: The Pharmaceutical industry sponsorship, research outcome and quality has been already evaluated for clinical trials in order to analyze if this kind of sponsorship affects the results of clinical trials. In this sense, this study has the aim to investigate whether placebo use allows positive outcomes regarding efficacy and safety compared to synthetic medicines. METHODS: We designed and registered a study protocol for a systematic review for methodology data. We will only randomized clinical trials that use placebo as comparator. The main outcome will be the evaluation of placebo use regarding the tendency for positive results (efficacy and security) when comparing to synthetic medicines. PubMed, Cochrane, LILACS (BVS), Web of Science, Scopus, and Excerpta Medica dataBASE (EMBASE) databases will be searched. Gray literature will be identified through the databases Proquest (Dissertation and Theses), OpenGrey and Google Scholar. Two review authors will independently assess trial quality and will extract data in accordance with standard Cochrane methodology. If necessary, we will also contact authors for additional information. The Cochrane Collaboration's risk of bias tool will be used. If feasible, it means homogenous data, we will conduct random effects meta-analysis. Subgroup analyses will be conducted for different justifications for placebo use and for studies sponsored/not sponsored by the pharmaceutical industry. RESULTS: Our present findings will indicate the effects of placebo use as comparator regarding efficacy and safety of the oral synthetic medicines. DISCUSSION: This systematic review will identify, summarize, and analyze if there is a trend for positive efficacy and safety results for synthetic medicines in clinical trials when compared with placebo and if the justification for placebo use is considered ethically acceptable. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42018110829 To introduce a drug product on the market, it must first be established that this product is safe and effective for the treatment of the disease to which it has been proposed. Besides, to verify these requirements, clinical studies in humans are carried out in several phases. [1] The safety assessment is related to the understanding that every medicine use presents risks, therefore, it is necessary to evaluate the risk-benefits of its use. The efficacy, however, considers the medicine's ability to achieve the expected diagnostic, prophylaxis and/or cure results for that particular molecule. In this sense, the safety and efficacy profile is based on a detailed assessment of the benefits related to the risks. [1] [2] The word placebo was first used, in the early 1960s, to refer to a product that had no activity to treat a certain condition. This product could be any therapeutic procedure that has an effect on the patient, symptom, syndrome or disease. [3] In addition to the product considered to be placebo itself, there is what is called the "placebo effect", this phenomenon occurs when a clinical result is obtained from the use of a product without an active ingredient. This phenomenon is still a mystery to modern medicine. This manifestation can be observed in several studies, mainly in those where symptoms such as pain are treated. [4] Many authors explain the "placebo effect" associating it with psychological manifestations of the individual Placebo has shown during the years activity in order to modulate some responses to the active treatments in conditions as pain, some surgeries, anxiety, Parkinson disease. Thus, it is possible to verify the psychological factor that the placebo can have to the people who use this product. [5] Although there is an improvement effect observed in some of the research participants with the use of placebo, it remains an inert product, without the addition of active principle, so its "action" is bound to psychological manifestations. Thus, the "placebo effect" does not justify the use placebo product as a comparator in a clinical study because it has no proven pharmacological activity that can interfere with the progression of the disease. [6] However, the use of placebo in clinical studies is still a widely used methodological tool since they have a negative control function during medical research. Placebos are generally products with the same physical characteristics of medicines that will be tested and administered, without, however, the natural therapeutic effect thereof. The fact that this product is "identical" to the tested medicine is of fundamental importance to enable the study to be blinded. [6] A comparison between the new and existing medicines or a placebo is imperative to assess the unique treatment benefits to the patient and knowledge of its risks. Those individuals in the negative control group, that is, those to whom a placebo is administered, are treated as a mere object of research. This practice demonstrates that there is not the least concern for the health of those subjects who are willing to help in that clinical study for the development of a new treatment, contrary to all ethical issues outlined in Good Clinical Practice. [7] Regarding the Declaration of Helsinki of the World Health Organization, the use of placebo is accepted in some situations. Except when there is no proven intervention, the use of placebo, or non-intervention, is acceptable; or when the use of placebo will not submit the subject to additional risks of serious or irreversible effects as a result of not receiving the best-proven intervention. Extreme care should be taken to avoid abuse of this option. [8] Even with the ethical restriction, some studies are performed using placebo as the comparator. In this sense, justifications of placebo use must be discussed and only accepted if the patients will not be exposed to unnecessary risks. For some authors, the only ethical arguments for placebo use is the inexistence of comparator, and there was doubt about the benefits of placebo use in prophylaxis studies. [9] The authors of some placebo-controlled trials do not uniformly agree that the use of placebo when a possible comparator is available is unethical. They believe that if patients are not harmed, such tests can ethically be carried out. Also, some studies with active control can present not reliable evidence of the effectiveness of a new therapy. [10] In this sense, the focus should be on the benefits for the patients. In this sense, it is essential to investigate if placebo use allows positive outcomes regarding efficacy and security compared to synthetic drug products. Besides, it is crucial to evaluate the relation of its use and pharmaceutical industry sponsorship and if the justification of use is considered ethically acceptable. This review protocol was registered at the PROSPERO platform under the number CRD42018110829. This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols checklist. [11] The present study protocol is being reported in accordance with the reporting guidance provided in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols statement [12] (see Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols checklist in Additional file 1). The acronym used for this question was PICO -participants, intervention, comparator, and outcomes. [13] For this study, the population was the subjects of clinical trials, the intervention was the synthetic oral drug products, the comparison was placebo, and the outcomes were positive efficacy and safety tendencies when testing synthetic drug products. Inclusion criteria: studies that had only 2 arms (placebo and synthetic drug) administered orally. Only phase III, randomized, double-blind studies were included in this systematic review. Primary outcome: The results of interest were drug efficacy, adverse effects, placebo effect, and ethical implications. Exclusion criteria: studies published in non-Latin alphabet, clinical trials with medical devices and diagnostic methods, clinical trials with non-synthetic drug products, non-randomized or observational clinical trials, studies with only 1 intervention arm or more than 2 arms, clinical trials with non-oral medicines, sublingually, more than 1 clinical trial per article, studies that present medicines with other pharmaceutical forms than tablets and use of other medicines concomitant with placebo. Studies that used concomitant medicines with placebo were included if the authors expressly mentioned that these medicines did not affect the outcome of the study. PubMed, Cochrane, LILACS (BVS), Web of Science, Scopus, and Excerpta Medica dataBASE (EMBASE) databases will be searched. Gray literature will be identified through the databases Proquest (Dissertation and Theses), OpenGrey and Google Scholar. Headings (MeSH) will be used in order to ensure uniform search terms. The search strategy will be piloted to ensure sufficient specificity and sensitivity. A draft search strategy The Rayyan system was used to evaluate abstracts and remove duplicates. [14] Randomized clinical trials that met all the inclusion criteria and passed the analysis of the exclusion criteria were evaluated in 2 phases. Phase 1: reading of all abstracts and selection of studies; phase 2: reading the full text and preparing the systematic review. Two independent reviewers (JA-S and CF) evaluated the quality of the trials and extracted the data following the standard Cochrane methodology, discrepancies resolved by a third participant (DM). Whenever necessary, they contacted the authors of the articles for additional information. From each study, we extracted study design, arms used at the study, medicine or medicine class, disease, number of industry and non-industry funded articles, location, inclusion and exclusion criteria, and the primary purpose of the study. Since many studies have the design mentioned above, that is, the use of placebo as a comparator considering another pharmaceutical product, the intended analysis of this study design was stratified regarding all the inclusion criteria. The initial flowchart about this data extraction is present at Figure 1 . The analysis of the included clinical studies was performed according to the Cochrane bias risk assessment. [15] Screening The data will be aggregate considering the different placebo use strategies across the different types of sponsorship and the different justifications for this use. Quantitative positive results for oral medicines when comparing to the placebo will also be included and interpreted. If data permits, the potential bias of publication, that is, the effect of the small sample studies and will be analyzed by the funnel chart and the Egger test. [16, 17] The heterogeneity between the studies will be assessed by inspection of the funnel plots for asymmetry and with Egger test, with small study effects when P values < .10. The heterogeneity between the studies was considered high if I 2 > 75%, moderate if 75%